Redeye retains its positive view on Transtema following a Q1 report with underlying sales and EBITA in line with our forecasts. From Q2 and onwards, Tessta, which had a solid start to 2022, will be fully consolidated, diving sales and earnings.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

© Modular Finance, source Nordic Press Releases